Below The Knee | Market Signal

When Capital Opens and Regulation Tightens: RegenLab IPO Leads, Sanuwave Falters, CMS Fluorescent Imaging Draft LCD Signals Diagnostic Headwind

Capital is flowing into wound care. RegenLab USA filed an S-1 with the SEC to list on Nasdaq under ticker RGNA, reporting $29.32 million in net product sales for H1 2026, up 21% year-over-year. The Swiss-founded regenerative medicine company, known for point-of-care PRP and cell processing devices, returned to operating profitability with $2.10 million operating income. A public listing would increase capital access and visibility for PRP-based wound and tissue regeneration products.

But it's not just going public. HARTMANN USA entered an exclusive national distribution agreement with SweetBio to commercialize VERIS, a collagen and Mānuka honey-based advanced wound care product, effective November 1. BioStem Technologies completed a $3 million private placement financing. Venture Medical acquired Medipyxis, a purpose-built wound care EMR platform targeting clinical documentation and workflow management for wound care practices. Novo Holdings invested in ForYou Medical to support global growth in advanced wound care manufacturing. OMEZA Holdings partnered with Spartan Medical to expand OCM wound matrix access across the federal healthcare market—VA, DoD, Indian Health Service.

Capital is opening on clinical validation too. Medtronic received FDA Breakthrough Device designation for IN.PACT BTK drug-coated balloon, signaling regulatory momentum for below-the-knee vascular intervention. Topical oxygen therapy is headed toward CMS coverage, strengthening AOTI's reimbursement pathway.

But regulation is tightening. Sanuwave Health received a Nasdaq delisting warning, signaling serious financial and compliance concerns for the wound care device company. And CMS released a draft Local Coverage Determination proposing non-coverage for fluorescent imaging in wound care diagnostics, signaling agency scrutiny on imaging-based assessment tools not directly tied to wound closure outcomes. This is draft-stage only, but it marks CMS positioning on diagnostic scope.

The story this week is bifurcation. Capital flowing into proven platforms with clear use cases and reimbursement pathways (RegenLab profitability, HARTMANN distribution, BioStem raise, Venture Medical workflow, Novo manufacturing, OMEZA federal access). Regulatory validation for clinical leaders (Medtronic Breakthrough, topical oxygen CMS pathway). But singular stress on generalists without differentiation (Sanuwave) and regulatory headwind on diagnostics without outcomes link (CMS fluorescent imaging draft).

When capital opens selectively, differentiation matters.

Regulatory | CMS Draft LCD Proposes Non-Coverage for Fluorescent Imaging in Wound Care Diagnostics

CMS released a draft Local Coverage Determination proposing non-coverage for fluorescent imaging in wound care diagnostics, signaling agency scrutiny on imaging-based assessment tools. The draft LCD indicates CMS skepticism toward fluorescent imaging modalities that are not directly linked to wound closure outcomes or clinical decision-making tied to reimbursable interventions. This is draft status only, but it marks CMS positioning on the diagnostic scope and reimbursement pathway for imaging-based wound assessment tools. The public comment period will determine final coverage determination.

The BTK read: CMS fluorescent imaging skepticism is outcomes-linking pressure on diagnostics. The agency is signaling: show us how this imaging changes treatment decisions and improves wound closure rates, or we're not paying. For diagnostic companies building fluorescent assessment tools, this is a reimbursement headwind. For companies with outcome-linked diagnostics, this clarifies the reimbursement case. Draft status means comment period is critical — watch for industry response.

Reimbursement | Topical Oxygen Therapy Headed Toward CMS Coverage

Topical oxygen therapy is progressing toward Medicare coverage determination, strengthening the reimbursement pathway for AOTI's TWO2 device and category-level access to advanced wound care options. This development signals CMS recognition of topical oxygen as a distinct therapeutic modality for diabetic foot ulcers unhealed after optimized standard care.

The BTK read: Topical oxygen CMS movement validates AOTI's clinical positioning. If coverage is granted, it expands the standard-of-care menu for DFU alongside NPWT and skin substitutes. AOTI becomes the category leader in topical oxygen. Watch for final coverage determination timeline.

Investment | RegenLab USA Files Nasdaq IPO Under RGNA

RegenLab USA has filed an S-1 with the SEC to list on Nasdaq under ticker RGNA, reporting $29.32 million in net product sales for H1 2026, up 21% year-over-year. The Swiss-founded regenerative medicine company, known for point-of-care PRP and cell processing devices, returned to operating profitability with $2.10 million operating income in H1 2026. A public listing would increase capital access and visibility for PRP-based wound and tissue regeneration products in the competitive biologics and skin substitutes market.

The BTK read: RegenLab's IPO is proof-of-concept for regenerative medicine scaling. $29M in H1 revenue with 21% growth and profitability is enterprise-scale validation. The public markets are signaling capital availability for regenerative wound care platforms. Watch for IPO valuation and whether the public markets reward PRP-based wound care positioning.

Market | HARTMANN USA Signs Exclusive Distribution Deal for SweetBio VERIS Wound Care

HARTMANN USA entered an exclusive national distribution agreement with SweetBio to commercialize VERIS, a collagen and Mānuka honey-based advanced wound care product, effective November 1, 2026. VERIS utilizes SweetBio's patented MX technology combining collagen derivative, Mānuka honey, and hydroxyapatite for acute and chronic wound management. The deal significantly expands VERIS market reach via HARTMANN's established national sales infrastructure, intensifying competition in the advanced wound dressing segment.

The BTK read: HARTMANN/SweetBio distribution is channel expansion play. HARTMANN's national infrastructure gives SweetBio immediate market access without building internal sales force. For HARTMANN, VERIS adds differentiated dressing to portfolio. This is how smaller innovators scale without IPO friction.

Investment | BioStem Technologies Completes $3 Million Private Placement

BioStem Technologies completed a $3 million private placement financing, demonstrating continued investor confidence in the company's surgical biologics and wound care strategy following its acquisition of BioTissue's surgical and wound-care business. The capital raise supports advancement of regenerative medicine applications across surgical and wound-care use cases.

The BTK read: BioStem's $3M raise validates surgical biologics positioning post-BioTissue. Capital availability for mid-cap biologics players remains strong. BioStem's strategic focus on regenerative medicine is attracting investor interest.

Market | Venture Medical Acquires Medipyxis, Wound Care EMR Platform

Venture Medical acquired Medipyxis, an electronic medical records and operating system purpose-built for wound care practices. The deal brings specialized clinical documentation and workflow management capabilities under Venture Medical's portfolio, targeting the administrative and compliance demands unique to wound care centers. This acquisition reflects growing investment in wound care-specific digital infrastructure as practices face increasing documentation burdens tied to reimbursement and coding requirements.

The BTK read: Venture Medical/Medipyxis acquisition is workflow consolidation. Wound care practices are drowning in documentation and compliance requirements. Purpose-built EMR addressing wound-care-specific workflows is competitive moat. This signals digital infrastructure becoming table stakes in wound care provider ecosystem.

Investment | Novo Holdings Invests in ForYou Medical for Advanced Wound Care Manufacturing Scale

Novo Holdings invested in ForYou Medical to support global growth in advanced wound care manufacturing. The investment signals institutional capital confidence in manufacturing scale-up for wound care biologics and dressings as demand for advanced wound care products grows globally.

The BTK read: Novo/ForYou manufacturing investment is supply-side validation. As wound care category grows (RegenLab IPO, SkinTE FDA approval, CAMP alternatives), manufacturing capacity becomes bottleneck. Novo's investment de-risks scaling and signals institutional confidence in category growth.

Market | OMEZA Expands Federal Wound Care Access Through Spartan Medical Partnership

OMEZA Holdings entered an exclusive partnership with Spartan Medical to make its FDA-cleared OCM wound matrix available to active-duty military, veterans, and Indian Health Service beneficiaries. The agreement expands OCM's reach across the federal healthcare market, leveraging Spartan Medical's VA and DoD commercialization and procurement infrastructure.

The BTK read: OMEZA/Spartan federal access is channel expansion into high-volume customer segments. VA and DoD are massive procurement entities. OCM gaining federal access is significant revenue opportunity and validates product positioning for complex wound management.

Regulatory | Medtronic Receives FDA Breakthrough Device Designation for IN.PACT BTK Drug-Coated Balloon

Medtronic received FDA Breakthrough Device designation for IN.PACT BTK drug-coated balloon, signaling regulatory momentum for drug-coated balloon technology in below-the-knee vascular intervention. The Breakthrough designation indicates the device addresses an unmet need in treating complex BTK peripheral artery disease and could accelerate FDA review pathway.

The BTK read: Medtronic IN.PACT BTK Breakthrough is regulatory validation for DCB technology in limb salvage territory. Breakthrough designation signals FDA recognizes this device addresses clinical need. Watch for IDE trial data and FDA approval timeline. If approved, DCB becomes standard-of-care option alongside atherectomy and stent strategies for complex BTK lesions.

Market | Sanuwave Health Receives Nasdaq Delisting Warning

Sanuwave Health received a Nasdaq delisting warning, signaling serious financial and compliance concerns for the wound care device company. This development raises questions about the company's ability to maintain operations and continue commercializing its MIST Therapy and other wound care technologies. For the BTK wound care market, a potential delisting could disrupt access to capital and undermine confidence in Sanuwave's long-term viability as a competitor.

The BTK read: Sanuwave delisting warning is singular stress signal. MIST Therapy ultrasound technology has clinical validation, but financial runway is exhausted. This is what happens when clinical validation doesn't translate to reimbursement momentum. For Sanuwave creditors, investors, and customers, the clock is ticking. Watch for bankruptcy filing, strategic asset sale, or restructuring announcement.

Woundcare, Limb Salvage, Foot and Ankle and Vascular, all scored, indexed and monitored. Real-time capital signals. Curated news and alerts. AI-powered queries. The way no market intelligence platform has done before.

intelligence.belowtheknee.co/sign-up →

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

Next stop: SAWC Fall in Las Vegas in two weeks.

-Scott